Wuhan Keqian Biology Co Ltd
SSE:688526
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Wuhan Keqian Biology Co Ltd
Wuhan Keqian Biology Co Ltd
Operating Income
Wuhan Keqian Biology Co Ltd
Operating Income Peer Comparison
600436
600276
000538
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Wuhan Keqian Biology Co Ltd
SSE:688526
|
Operating Income
¥395m
|
CAGR 3-Years
17%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Operating Income
¥2.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Operating Income
¥3.5B
|
CAGR 3-Years
21%
|
CAGR 5-Years
22%
|
CAGR 10-Years
22%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Operating Income
¥4.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
1%
|
CAGR 10-Years
12%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Operating Income
¥3.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Operating Income
-¥749.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Wuhan Keqian Biology Co Ltd's Operating Income?
Operating Income
395m
CNY
Based on the financial report for Dec 31, 2022, Wuhan Keqian Biology Co Ltd's Operating Income amounts to 395m CNY.
What is Wuhan Keqian Biology Co Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
2%
Over the last year, the Operating Income growth was -33%. The average annual Operating Income growth rates for Wuhan Keqian Biology Co Ltd have been 17% over the past three years , 2% over the past five years .
You don't have any saved screeners yet
